WO2002086132A3 - Viral vector system to transduce or infect a target adipose tissue site - Google Patents
Viral vector system to transduce or infect a target adipose tissue site Download PDFInfo
- Publication number
- WO2002086132A3 WO2002086132A3 PCT/GB2002/001830 GB0201830W WO02086132A3 WO 2002086132 A3 WO2002086132 A3 WO 2002086132A3 GB 0201830 W GB0201830 W GB 0201830W WO 02086132 A3 WO02086132 A3 WO 02086132A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adipose tissue
- transduce
- infect
- viral vector
- vector system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002251310A AU2002251310A1 (en) | 2001-04-20 | 2002-04-19 | Viral vector system to transduce or infect a target adipose tissue site |
EP02720242A EP1385969A2 (en) | 2001-04-20 | 2002-04-19 | Viral vector system to transduce or infect a target adipose tissue site |
US10/690,320 US20050106732A1 (en) | 2001-04-20 | 2003-10-20 | Vector system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0109781A GB0109781D0 (en) | 2001-04-20 | 2001-04-20 | Vector system |
GB0109781.5 | 2001-04-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/690,320 Continuation-In-Part US20050106732A1 (en) | 2001-04-20 | 2003-10-20 | Vector system |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002086132A2 WO2002086132A2 (en) | 2002-10-31 |
WO2002086132A3 true WO2002086132A3 (en) | 2003-05-08 |
Family
ID=9913181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/001830 WO2002086132A2 (en) | 2001-04-20 | 2002-04-19 | Viral vector system to transduce or infect a target adipose tissue site |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1385969A2 (en) |
AU (1) | AU2002251310A1 (en) |
GB (1) | GB0109781D0 (en) |
WO (1) | WO2002086132A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049827A2 (en) * | 1996-06-26 | 1997-12-31 | Cornell Research Foundation, Inc. | Adenoviral mediated gene transfer in adipocytes and related implants |
WO1998013071A1 (en) * | 1996-09-24 | 1998-04-02 | Merck & Co., Inc. | Gene therapy for inhibition of angiogenesis |
GB2327224A (en) * | 1997-07-09 | 1999-01-20 | Mayo Foundation | Gene transfer to adipocytes |
-
2001
- 2001-04-20 GB GB0109781A patent/GB0109781D0/en not_active Ceased
-
2002
- 2002-04-19 AU AU2002251310A patent/AU2002251310A1/en not_active Abandoned
- 2002-04-19 WO PCT/GB2002/001830 patent/WO2002086132A2/en not_active Application Discontinuation
- 2002-04-19 EP EP02720242A patent/EP1385969A2/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049827A2 (en) * | 1996-06-26 | 1997-12-31 | Cornell Research Foundation, Inc. | Adenoviral mediated gene transfer in adipocytes and related implants |
WO1998013071A1 (en) * | 1996-09-24 | 1998-04-02 | Merck & Co., Inc. | Gene therapy for inhibition of angiogenesis |
GB2327224A (en) * | 1997-07-09 | 1999-01-20 | Mayo Foundation | Gene transfer to adipocytes |
Non-Patent Citations (3)
Title |
---|
KAFRI T: "Lentivirus vectors: difficulties and hopes before clinical trials.", CURRENT OPINION IN MOLECULAR THERAPEUTICS. ENGLAND AUG 2001, vol. 3, no. 4, August 2001 (2001-08-01), pages 316 - 326, XP001097685, ISSN: 1464-8431 * |
KIM V N ET AL: "MINIMAL REQUIREMENT FOR A LENTIVIRUS VECTOR BASED ON HUMAN IMMUNODEFICIENCY VIRUS TYPE 1", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 1, January 1998 (1998-01-01), pages 811 - 816, XP000872453, ISSN: 0022-538X * |
TRONO D: "LENTIVIRAL VECTORS: TURNING A DEADLY FOE INTO A THERAPEUTIC AGENT", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, 2000, pages 20 - 23, XP000916379, ISSN: 0969-7128 * |
Also Published As
Publication number | Publication date |
---|---|
EP1385969A2 (en) | 2004-02-04 |
AU2002251310A1 (en) | 2002-11-05 |
WO2002086132A2 (en) | 2002-10-31 |
GB0109781D0 (en) | 2001-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002074337A8 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
EP1918300A3 (en) | Peptide-based immunization therapy for treatment of atherosclerosis | |
AU2003278816A1 (en) | ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | |
WO2001089457A3 (en) | Thrombopoietin mimetics | |
WO2003032916A3 (en) | Organosulfur inhibitors of tyrosine phosphatases | |
WO2002060955A3 (en) | Modified antibodies and methods of use | |
WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
WO2003034995A3 (en) | Integrin targeting compounds | |
AU2001235006A1 (en) | Prophylactic and therapeutic monoclonal antibodies | |
WO2003041686A3 (en) | Improved therapy for topical diseases | |
AU2002248319A1 (en) | Pharmaceutical composition for the prevention and treatment of scar tissue | |
BR9611897A (en) | Benzofuran carboxamides and sulfonamides | |
WO2001013899A3 (en) | Therapeutic system containing an active substance and comprising at least two polymerous layers | |
WO2002092044A3 (en) | Use of electrolytes for reinforcing the barrier function of the skin | |
WO2001051511A3 (en) | Recombinant production of human histone-1 subtypes and use thereof for therapeutic purposes | |
WO2002086132A3 (en) | Viral vector system to transduce or infect a target adipose tissue site | |
WO2003007876A3 (en) | N-fatty acid-amino acid conjugates and therapeutic uses | |
AU3247201A (en) | Gene therapy to promote angiogenesis and/or the treatment of heart failure | |
WO2003022224A3 (en) | Cox-2 function and wound healing | |
AU2002316604A1 (en) | Peptides which modulate blood coagulation and methods of use thereof | |
WO2003045428A3 (en) | Use of a technically modified cell as a vaccine for treating tumoral disease | |
WO1999047652A3 (en) | Novel rnase-like protein and its use | |
WO2002044328A3 (en) | Anti-angiogenic polypeptides | |
AU5611701A (en) | Agent for the diagnosis and therapy of viral diseases | |
AU6690898A (en) | Composition for the treatment of exercise induced pulmonary hemorrhage and inhaler for administering said composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10690320 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002720242 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002720242 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |